Collette Rawnsley

October 30, 2022

Collette Rawnsley is the head of European IP policy and advocacy at Nokia Technologies. Collette has extensive experience in providing strategic advice on regulatory and policy matters regarding IP licensing in the technology and media sectors, including standard essential patents, FRAND disputes, and patent pools. Before joining Nokia in January 2021, she spent 15 years in private practice in London and Brussels and was involved in some of the leading cases concerning the intersection of IP and competition law. Collette was the head of EU Competition at Wiggin LLP, a law firm specializing in media, technology and intellectual property. Previously, she was counsel at Shearman & Sterling LLP. Before entering private practice, Collette was senior Référendaire at the UK Competition Appeal Tribunal and a lawyer in the UK Government Legal Department.

Securing the Future of the U.S. Biopharmaceutical Industry: The Most-Favored-Nation Paradox

February 5, 2026

By Sujai Shivakumar and Anne Pritchett The Trump administration is pursuing lowering prescription drug costs primarily to end what it describes as “global freeloading” and to ensure U.S. patients pay prices comparable to those in other developed nations. The administration argues that while the United States represents less than 5 percent

Universities, Patents, and the Future of U.S. Competitiveness

December 15, 2025

By Shruti Sharma and Chris Borges Universities are among the most powerful engines of U.S. innovation, transforming federal research investments into scientific discoveries that underpin economic growth, technological leadership, and national security. Current law, via the Bayh-Dole Act, allows universities to patent inventions and license them to private companies, with royalties

How Counterfeit Drugs Threaten U.S. Health and Innovation

November 19, 2025

By Anne Pritchett According to the Department of Homeland Security, counterfeit drugs “threaten national security and public safety directly when introduced into government and critical infrastructure supply chains, and indirectly if used to generate revenue for transnational criminal organizations.” Furthermore, counterfeit drugs harm pharmaceutical innovation by eroding profitability and investor